Back to Journals

Cancer Management and Research


Professor Onel

Professor of Pediatrics at Hofstra Northwell School of Medicine;Professor of Genetics, Feinstein Institute, Director of Clinical Genomics at Northwell Health, United States

Professor Onel

Editor-in-Chief: Dr Kenan Onel

Dr Onel is a graduate of Yale University and received both his MD and his PhD in molecular biology from Cornell University Medical College.  He completed his residency in pediatrics at Babies and Children's Hospital of New York (Columbia University) and his fellowship in pediatric hematology/oncology at the Memorial Sloan-Kettering Cancer Center. Before joining Northwell Health in September, 2016, Dr Onel served on the faculty of the University of Chicago for 12 years as the director of the Familial Cancer Clinic in the Department of Pediatrics.  He currently oversees an active research program studying genetic susceptibilities to cancer, for which he has been the recipient of a number of grants and awards.

 


Dr D'Anneo

Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, Italy

Dr D'Anneo

Associate Editor: Antonella D'Anneo

Dr. D’Anneo earned a Master Degree with full marks and honors in Biological Sciences (curriculum in molecular biology) from the University of Palermo in 2000 and obtained a Ph.D. in Experimental Oncobiology in 2004.
She began her studies on the field of tumor biology, cell death mechanisms and biochemical pathways that can be activated in tumor cells. Her scientific production is characterized by manuscripts on researches performed to elucidate the mode of action of apoptotic drugs and the possible synergistic interactions when drugs are employed in combination studies.  To complement the graduate training in biochemistry, Dr. D'Anneo obtained, as visiting scholar, a training at Rangos Research Center (Children's Hospital, School of Medicine, University of Pittsburgh, PA-USA). During this stage (2005-2007), she was directly involved in the study of Adenoviral and EIA (Equine infectious anemia) viruses in blocking cytokine-induced apoptosis in both human and murine pancreatic ß islets. She also took part in a research project concerning gene therapy approaches to determine tolerizzation of diabetic patients against the cells of islet donor.
During her career, she had acquired expertise in the study of many different types of cell death (apoptosis, necrosis, necroptosis, autophagy and anoikis) activable in vitro tumor systems and the role of oxidative stress in cancer. Dr. D’Anneo made significant contributions to researches on combinations of sesquiterpene lactones (parthenolide), HDAC inhibitors (SAHA, Trichostatin A and sodium butyrate), proteasome inhibitors (MG132, lactacystin and Velcade) and recombinant Trail in vitro studies for the treatment of many different cancer systems. She is also the co-inventor of a patent for combined therapies for the treatment of liver tumors.

In the recent years she was also focused on the study of the serpin proteinase inhibitor 9 (PI-9) in ER+ breast cancer cells and breast cancer stem-like cells.
She is currently an Assistant Professor in Biochemistry at the Department of Sciences and Biological, Chemical and Pharmaceutical Technologies, School of Basic and Applied Sciences, University of Palermo and serves as mentor of PhD and students of the MSc in Molecular and Health Biology.


Dr Drusbosky

Hematology Oncology, University of Florida, United States

Dr Drusbosky

Associate Editor: Leylah Drusbosky

Dr. Drusbosky is a Research Assistant Professor in the College of Medicine and the Scientific Director of iCare for Cancer Patients, a precision oncology program at the University of Florida. Her research interests combine cancer genetics with computational biology to illuminate aberrant signaling pathways within hematological malignancies, and identify novel combinations of therapeutics to target each patient’s unique cancer mutanome. Dr. Drusbosky is developing assays to non-invasively monitor patient’s response to therapy, and detect relapsing disease before clinically indicated.
Additional research interests include the protective bone marrow microenvironment as related to leukemia and myelodysplastic syndromes, xenograft models of myeloid malignancies, biomarker and drug discovery, and gene expression profiling of tumor cells. 


Prof. Dr. Fernandes

Faculdade Ciências e Tecnologia, Universidade Nova, Portugal

Prof. Dr. Fernandes

Associate Editor: Prof. Dr. Fernandes 

Dr. Fernandes is an Assistant Professor at Faculdade de Ciências e tecnologia, Universidade NOVA de Lisboa, Portugal. She obtained her PhD in Biotechnology from Instituto Superior Técnico, Universidade de Lisboa after earning her graduation degree in Chemical Engineering/Biotechnology also from the same institution in Lisbon, Portugal. Dr. Fernandes is an expert research scientist that combines chemistry, biochemistry, molecular biology and human molecular genetics. Her research interests have been focussed on cancer diagnostics, biomarkers identification and validation, drug screen and validation using in vitro and in vivo models and in the development of novel combinatorial therapies. In 2013, she has translated part of her research into a private Diagnostics company. Dr. Fernandes has 5 book chapters, and more than 65 papers published in peer reviewed journals. Dr. Fernandes serves as reviewer for more than 8 reputable journals.


Professor Nakshatri

Indiana University School of Medicine, United States

Professor Nakshatri

Associate Editor: Dr Harikrishna Nakshatri 

Dr. Nakshatri’s research interests are on heterogeneity in normal breast, the mechanisms of anti-estrogen resistance and metastasis in breast cancer. Ongoing research in his lab includes elucidating the mechanisms by which the serine/threonine kinase AKT alters estrogen signaling and confers anti-estrogen resistance. His laboratory has identified and commercialized biomarkers that may predict response to anti-estrogen therapy. His laboratory was the first to demonstrate constitutive activation of NF-kappaB in a subset of breast cancer. Activated NF-kappaB confers chemotherapy resistance and enhances metastasis. His laboratory is also investigating the mechanisms of organ-specific metastasis and the role of cancer stem cells in chemoresistance and metastasis. Using the normal breast tissue from Susan G. Komen for the Cure Tissue Bank, his group has shown ethnicity-dependent and ethnicity-independent heterogeneity in normal breast. His group has also established a culturing method to grow tumors, and tumor adjacent-normal, and metastasis to genomically characterize tumors/metastasis at single cell level. NIH, Department of Defense, American Cancer Society, Susan G. Komen for Cure, Department of Veterans Affairs and other private foundations funded his research. He is the author or co-author of >120 publications with >12,500 citations. He has served/serving in scientific review committees of NIH, Department of Defense, Italian Association for Cancer Research, and Susan G. Komen for Cure. He is one among 52 breast cancer researchers who serve as Susan G. Komen Scholars (2010-2020). He is currently a member of the NIH Cancer Molecular Pathobiology Study Section.  He is also in the editorial boards of scientific journals and an Associate Editor of Cancer Research. He has trained over 20 post-doctoral fellows, surgical residents, and medical students. In his role as the Associate Director of Education at the Indiana University Simon Cancer Center (IUSCC), he is responsible for developing educational activities of the cancer center and a training program in cancer biology.


Professor Sun

Department of Cell Systems & Anatomy, University of Texas Health Science Center, United States

Professor Sun

Associate Editor: Dr. LuZhe Sun

Dr. LuZhe Sun received his Ph.D. in Physiology from Rutgers University and UMDNJ-Robert Wood Johnson Medical School in 1990 and obtained his postdoctoral training in Baylor College of Medicine in the US. He is currently Professor, Dielmann Endowed Chair in Oncology, and Associate Director for Basic Research at his NCI-designated cancer center. Dr. Sun’s research is focused on investigating molecular mechanisms of tumorigenesis and metastasis, and novel experimental therapeutics in various models of carcinomas. His research has been supported with multi-million dollar grants from NIH, DOD, CPRIT, and other private foundations. He is an elected AAAS Fellow.


Editorial Board

Laure Aurelian, Professor of Pharmacology and Microbiology and Immunology, Department of Pharmacology, University of Maryland School of Medicine, Baltimore Maryland.

Prof. Franky Leung Chan, Professor, Cancer Biology and Experimental Therapeutics, School of Biomedical Sciences, Chinese University of Hong Kong, Shatin, Hong Kong

Professor Brendon Coventry, Associate Professor of Surgery, Discipline of Surgery, University of Adelaide, Royal Adelaide Hospital, South Australia, Australia 5000

Bilikere Dwarakanath, Professor (Research), Central Research Facility, Sri Ramachandra University, Chennai, India

Alfio Ferlito, Professor of Otorhinolaryngology-Head and Neck Surgery, Coordinator of the International Head Neck Scientific Group (www.IHNSG.com)

Randall F Holcombe, MD, MBA, Director, University of Hawaii Cancer Center, Honolulu, HI, USA

Gary L Johanning, Program Director - Viral Oncology & Immunology, Discovery Biology Section, SRI International, Menlo Park, CA, USA

Cheryl L. Jorcyk, Director, Clinical/Translation Research, Professor of Biological Sciences, Boise State University, Boise, ID, USA

Kattesh V Katti, Distinguished Curators’ Professor of Radiology and Physics; Margaret Proctor Mulligan Distinguished Chair; Professor of Cancer Research; Director, Institute of Green Nanotechnology, University of Missouri Medical School, Columbia, MO, USA

Evan Keller, Professor, Department of Urology and Pathology, University of Michigan, Ann Arbor, MI, USA

Thomas V Merluzzi, Professor, Department of Psychology, Laboratory for Psycho-oncology Research, University of Notre Dame, Notre Dame, IN, USA

Silvana Morello, PhD, Assistant Professor of Clinic Pharmacology and Immunopharmacology, Department of Pharmacy, University of Salerno, Salerno, Italy.

Rudolph M Navari, Professor of Medicine, Division of Hematology Oncology, University of Alabama at Birmingham School of Medicine; Senior Scientist, Experimental Therapeutics Program, UAB Comprehensive Cancer Center, Birmingham, AL, USA

Errol Philip, Notre Dame Laboratory for Psycho-oncology Research, University of Notre Dame, Notre Dame, IN, USA

Johnson Stanslas, Professor, Pharmacotherapeutics Unit, Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Malaysia

Friedrich Stölzel, Department of Internal Medicine I, University Hospital Dresden, Germany

Prof. Andrzej Stepulak, MD.Ph.D, Department of Biochemistry and Molecular Biology, Medical University in Lublin, Lublin, Poland.

Armin D Weinberg, Clinical Professor Baylor College of Medicine; Adjunct Professor Rice University; Adjunct Professor Texas A&M University School of Public Health, TX, USA

Kexin Xu, Assistant Professor, Department of Molecular Medicine, the University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

Jing Zhang, Professor in Department of Pathology, State Key Laboratory of Tumor Biology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China.